Magnitude Biosciences Ltd performed whole-organism RNAseq on C. elegans treated with Compound X to understand its molecular basis.

Public source

Publisher name

Public post

This week, we conclude our end-to-end Case Study series, 📚 ➜🎯 ➜ 💊 From Library to Molecule For companies sitting on a #compoundlibrary in need of #repurposing, this o…

Log in to read the full post

Company

About Magnitude Biosciences Ltd

An innovative C. elegans company, using our expertise and technology to provide quantified non-invasive assays of health outcomes for biotech, nutrition and other industries and research interests. - Prescreen compounds to reduce the number of experiments in mammals - Find effective and safe concentration ranges
 - Test mutants in signalling pathways - Screen libraries of mutants
 - Screen compound libraries 
 - Combine compounds and mutants
 - Adapt technology to address your questions We are a team of experts with a proven track record of: Designing customised C. elegans studies to provide answers to your specific ageing research questions Integrating C. elegans into drug discovery pipelines Working with innovative biotech and pharma companies Providing relevant, standardised, data rich assays

See more

Latest activity

8 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.